Recent progresses of targeted therapy and immunotherapy of hepatocellular carcinoma
10.3760/cma.j.cn371439-20230605-00130
- VernacularTitle:肝细胞癌的靶向及免疫治疗新进展
- Author:
Shan JIANG
1
;
Ximing XU
Author Information
1. 武汉大学人民医院肿瘤中心，武汉 430060
- Keywords:
Carcinoma, hepatocellular;
Molecular targeted therapy;
Immunotherapy
- From:
Journal of International Oncology
2023;50(11):688-695
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma (HCC) is one of the most common malignancies in the world, with a high incidence and fatality rate in China. Since sorafenib opened up a new era of targeted therapy for HCC, drug developers around the world have made a lot of efforts and contributions to the exploration of systematic therapy for HCC. In recent years, novel molecular targeted agents, immune checkpoint inhibitors and their combined treatment regimens in advanced HCC have been implemented for many large samples, international multi-center clinical trials. The results show that the therapeutic effect of immunotherapy combined with targeted therapy and dual immunotherapy have significant advantages compared with that of targeted or immune monotherapy, and have satisfactory safety while prolonging survival and improving the quality of life of patients.
